Abstracts tagged "Outcome measures"

Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting
Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Alan R. Erickson², Chia-Chen Teng³, Tina Huynh³, Sharon Austin⁴, Bradley S. Stolshek⁵, Alex Mutebi⁶, David Collier⁵, Sally W. Wade⁷ and Brian Sauer³, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴VAMC, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Amgen, Thousand Oaks, CA, ⁶Global Health Economics, Amgen, Thousand Oaks, CA, ⁷Wade Outcomes Research and Consulting, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…
Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Maarten Boers^1,2, Sarah Leatherman³, James R. O'Dell⁴ and Jeffrey R. Curtis⁵, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ³MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Birmingham VAMC, Birmingham, AL
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…
Abstract Number: 2223 • 2015 ACR/ARHP Annual Meeting
Improving Clinical Decisions for Rheumatoid Arthritis Management Using Online Medical Simulations
Nimish Mehta¹, Keith Johnson², Douglas Blevins³ and Martin Warters³, ¹Medscape, LLC, New York, NY, ²Medscape Education, New York, NY, ³Medscape, LLC, Durham, NC
Background/Purpose: In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled, and only a minority of patients attain the goal of consistent…
Abstract Number: 2224 • 2015 ACR/ARHP Annual Meeting
Tailored, Online Education on Comparative Effectiveness Studies in Rheumatoid Arthritis: Success in Improving Knowledge and Clinical Decisions
Nimish Mehta, Emilie McCardell and Kathleen Geissel, Medscape, LLC, New York, NY
Background/Purpose: Analysis of past educational activities on comparative effectiveness studies in RA identified different educational needs for varying segments of rheumatologists – from interpretation of…
Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Kathleen Andersen¹, Daming Lin², Susan J. Bartlett^3,4, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰, Diane Tin¹¹, J Carter Thorne¹², VP Bykerk^13,14 and CATCH Investigators, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
Abstract Number: 2330 • 2015 ACR/ARHP Annual Meeting
The Turkish Validity and Reliability of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL)
M Tuncay Duruoz¹, Canan Sanal Top², Ilhan Sezer³, Figen Yılmaz⁴, Cagri Ünal², Hatica Sule Baklacioglu⁵, Firat Ulutatar⁶ and Pamir Atagunduz⁷, ¹Dept of PM&R, Rheumatology Clinic, Marmara University Medical School, Istanbul, Turkey, ²PM&R, Marmara University Medical School, Istanbul, Turkey, ³Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, ⁴PM&R, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey, ⁵Rheumatology, Marmara University Medical School, Istanbul, Turkey, ⁶Physical Medicine and Rehabilitation Department, Marmara University Medical School, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) is a disease-specific measure of needs-based quality of life developed in the United Kingdom (1).…
Abstract Number: 158 • 2015 ACR/ARHP Annual Meeting
Ultrasound Score of Dominant Hand in Patients with Rheumatoid Arthritis Correlates with DAS28CRP, CDAI and SDAI but Not RAPID-3
Allen P. Anandarajah¹, Bethany Marston², Linda Grinnell-Merrick² and Ralf G. Thiele³, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Musculoskeletal ultrasound (MUS) allows for direct visualization of diverse pathologic features such as cortical bone erosions, synovial thickening, and synovial vascularity in the joints…
Abstract Number: 2539 • 2015 ACR/ARHP Annual Meeting
The Validity and Reliability of Turkish Version of the Jenkins Sleep Scale in Rheumatoid Arthritis
M Tuncay Duruoz¹, Cagri Ünal², Firat Ulutatar³, Canan Sanal Top² and Osman Hakan Gunduz⁴, ¹Dept of PM&R, Rheumatology Clinic, Marmara University Medical School, Istanbul, Turkey, ²PM&R, Marmara University Medical School, Istanbul, Turkey, ³Physical Medicine and Rehabilitation Department, Marmara University Medical School, Istanbul, Turkey, ⁴Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The Jenkins Sleep Scale has 4 questions to assess the estimation of sleep problems in clinical research. It was developed in USA (1). Aim: To…
Abstract Number: 190 • 2015 ACR/ARHP Annual Meeting
Ultrasound Imaging with Elastography for the Medical Treatment of Dupuytren’s Contracture
Paul John DeMarco¹, Alan K. Matsumoto¹, Nicole Thomas², Megan Bishop¹, Andrew Gregory DeMarco³, Guada Respicio¹, Ashley Beall¹, Robert Rosenberg¹, Theresa Bass-Goldman¹ and Herbert S. B. Baraf¹, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Rheumatology, Georgetown University Hospital, Washington DC, DC, ³Duquesne University, Pittsburgh, PA
Background/Purpose: Dupuytren’s contracture is a rheumatic disease characterized by an fibrotic reaction in the palmar aponeurosis, resulting in disability. Medical treatment with up to 3…
Abstract Number: 2596 • 2015 ACR/ARHP Annual Meeting
Less Musculoskeletal Ultrasound Power Doppler Activity Seen in Obese Rheumatoid Arthritis
Erin Bauer¹, Ami Ben-Artzi², Erin Duffy¹, David Elashoff¹, Cesar Olmos³ and Veena K. Ranganath³, ¹Medicine, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, Los Angeles, CA, ³Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Studies report that obese and overweight patients with rheumatoid arthritis (RA) are less likely to attain remission and more likely to have limited therapeutic…
Abstract Number: 438 • 2015 ACR/ARHP Annual Meeting
Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis
Arvind Chopra¹, Manjit Saluja², Alastair Knight³, Lucy Shneyer⁴, Cheryl Lassen⁵, Michael Wyand⁶ and Jonathan Kay⁷, ¹Rheumatology, Centre for Rheumatic Diseases, Pune 411001, India, ²Centre for Rheumatic Diseases, Pune 411001, India, ³Data Management, Evicom Ltd, Twickenham, United Kingdom, ⁴Shneyer Statistics, Denville, NJ, ⁵Epirus Biopharmaceuticals, Zug, Switzerland, ⁶Epirus Biopharmaceuticals, Boston, MA, ⁷University of Massachussets Medical School, Worcester, MA
Background/Purpose: The Stanford Health Assessment Questionnaire (HAQ) includes several questions that are more relevant to rheumatoid arthritis (RA) patients in Western countries than to those…
Abstract Number: 2646 • 2015 ACR/ARHP Annual Meeting
Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity
Helga Radner¹, Paul Studenic², Stanley B. Cohen³, N Shadick⁴, C Iannaccone⁵, Elisabeth Lie⁶, Maria Dahl Mjaavatten⁶, Meredith Leigh Cohen³, Josef S. Smolen⁷ and Daniel Aletaha⁸, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Division of Rheumatology, Immunology & Allergy, Brigham and Women's Hosp, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of Medicine 3, Division of Rheumatology, Medical Univ Vienna, Vienna, Austria, ⁸Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment of disease activity (PtGA) is a key variable in assessing RA disease activity and remission (REM). Typically assessed on a…
Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.